Replies to post #218728 on Biotech Values

[DewDiligence]

Mavyret has #1 or close to #1 position in every major market, according to ABBV CEO on 1Q18 CC.

[DewDiligence]

(ENTA)—EPVantage, which is normally a trustworthy provider of educated biotech opinion, is hedging like a sell-side analyst wrt ABBV's $3.5B HCV guidance:

https://twitter.com/DewDiligence/status/990031812377436162

[DewDiligence]

ABBV “Dutch auction” tender for $7.5B of stock—price range is $99.00-114.00:

https://www.prnewswire.com/news-releases/abbvie-commences-self-tender-offer-for-up-to-7-5-billion-of-its-common-stock-300639738.html

[DewDiligence]

Poll re 2Q18 Mavyret sales:
https://twitter.com/DewDiligence/status/1020413905552723970

Background info re poll:
https://twitter.com/DewDiligence/status/1020445743893680128

[DewDiligence]

ABBV/ENTA 2Q18 HCV sales=$973M (+6% QoQ)—$422M US; $551 ex-US:

https://finance.yahoo.com/news/abbvie-reports-second-quarter-2018-113800172.html